Monte Rosa Therapeutics, Inc.
General ticker "GLUE" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $872.6M (TTM average)
Monte Rosa Therapeutics, Inc. follows the US Stock Market performance with the rate: 30.0%.
Estimated limits based on current volatility of 2.4%: low 13.58$, high 14.56$
Factors to consider:
- Total employees count: 150 (+11.9%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Operational and conduct risks, Regulatory and compliance, Clinical trial delays, Capital raising failure, Labor/talent shortage/retention
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [7.43$, 17.53$]
- 2026-12-31 to 2027-12-31 estimated range: [5.25$, 13.00$]
Financial Metrics affecting the GLUE estimates:
- Negative: with PPE of -36.6 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -2.11 <= 0.28
- Negative: negative Net income
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: 42.26 < Shareholder equity ratio, % of 51.95 <= 63.63
- Positive: -14.39 < Investing cash flow per share per price, % of -9.43
Short-term GLUE quotes
Long-term GLUE plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $75.62MM | $123.67MM |
| Operating Expenses | $143.31MM | $156.73MM | $177.88MM |
| Operating Income | $-143.31MM | $-81.11MM | $-54.21MM |
| Non-Operating Income | $8.30MM | $10.98MM | $14.48MM |
| R&D Expense | $111.27MM | $121.56MM | $141.50MM |
| Income(Loss) | $-135.01MM | $-70.13MM | $-39.72MM |
| Taxes | $0.34MM | $2.57MM | $-1.10MM |
| Net Income(Loss)* | $-135.35MM | $-72.70MM | $-38.63MM |
| Stockholders Equity | $179.25MM | $222.94MM | $233.06MM |
| Assets | $303.75MM | $438.73MM | $448.66MM |
| Operating Cash Flow | $-43.80MM | $42.00MM | $-22.80MM |
| Capital expenditure | $19.04MM | $3.99MM | $4.70MM |
| Investing Cash Flow | $88.80MM | $-44.45MM | $-101.83MM |
| Financing Cash Flow | $27.49MM | $98.89MM | $30.35MM |
| Earnings Per Share** | $-2.63 | $-0.98 | $-0.59 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.